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Abstract
Since Hsp90 modulates all six hallmarks of cancer simultaneously, it has become an attractive
target for the development of cancer chemotherapeutics. In an effort to develop more efficacious
compounds for Hsp90 inhibition, novobiocin analogues were prepared by replacing the central
coumarin core with naphthalene, quinolinone, and quinoline surrogates. These modifications
allowed for modification of the 2-position, which was previously unexplored. Biological
evaluation of these compounds suggests a hydrophobic pocket about the 2-position of novobiocin.
Anti-proliferative activities of these analogues against multiple cancer cell lines identified 2-
alkoxyquinoline derivatives to exhibit improved activity.
Introduction
Heat shock protein 90 (Hsp90) is one of the most abundant molecular chaperones in the cell,
is highly conserved in both eukaryotes and prokaryotes, and plays a key role in protein
homeostasis.1,2 Hsp90-dependent proteins are responsible for cellular growth, signaling,
differentiation, survival and protection against misfolded proteins. More than 200 client
proteins are dependent upon Hsp90 for activation and/or stability; a quarter of which are
directly associated with cell growth or signaling.3 Several Hsp90-dependent clients are
found in pathways that are commonly mutated or hijacked during oncogensis.4
Consequently, Hsp90 is overexpressed in cancer cells to maintain cellular homeostasis under
such environments and to serve as a buffer within tumor cells.5,6 Since Hsp90 modulates
© 2013 Elsevier Ltd. All rights reserved.
*Author to whom correspondence should be addressed: Phone: (785) 864-2288. Fax: (785) 864-5326. bblagg@ku.edu.
Supporting Information Available: Experimental procedures and characterization for all new compounds.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Bioorg Med Chem. Author manuscript; available in PMC 2015 February 15.
Published in final edited form as:













multiple pathways simultaneously, its inhibition produces a mechanism to overcome
resistance that results from the inhibition of a single protein.7–9 Therefore, inhibition of
Hsp90 for the treatment of cancer represents a powerful paradigm for drug
development. 10–12
Structurally, Hsp90 exists as a homodimer and possesses two nucleotide binding regions:
The N-terminal ATP-binding pocket is required for ATPase activity and produces the
requisite energy for client protein maturation.13–15 The C-terminal nucleotide binding
pocket exhibits allosteric control over both substrates and the N-terminal ATP-binding
site.16 The N-terminal ATP binding site is inhibited by the natural products radicicol and
geldanamycicn.17 The C-terminal region contains a dimerization motif that modulates client
protein release. N-Terminal inhibitors have been widely studied in both academia and the
pharmaceutical industry, and some have advanced to clinical trials.18 In contrast, the C-
terminal inhibitors have not advanced into clinical investigations thus far, and the most
significant reason is likely the absence of a co-crystal structure bound to an inhibitor.19 The
development of more efficacious C-terminal inhibitors is desired to better understand the
ramifications of C-terminal inhibition and to probe the mechanism by which Hsp90 interacts
with client proteins. As an anti-cancer agent, Hsp90 C-terminal inhibitors manifest a distinct
advantage over N-terminal inhibitors, as they do not induce the pro-survival heat shock
response, which is a deleterious consequence of N-terminal inhibition.20 Consequently, the
development of the Hsp90 C-terminal inhibitors represents an intense area of research.21–26
Novobiocin is a potent inhibitor of bacterial DNA gyrase and was also identified as the first
Hsp90 C-terminal inhibitor alongside chlorobiocin and coumermycin (Figure 1).27–29
However, due to its low efficacy against cancer cells (IC50 ~ 700 μM), it was considered
unsuitable for further evaluation as an Hsp90 inhibitor. Subsequent studies led to
identification of some structure-activity relationships for novobiocin that resulted in KU-174
and DHN1, which manifest low micromolar activity. Additional studies led to compounds
that exhibit greater potency and solubility than novobiocin and contained surrogates of the
stereochemically complex noviose sugar as well as structural modifications to the
benzamide side chain.23,30–33 The improved analogues exhibit mid nanomolar inhibitory
activity against several cancer cell lines, while simultaneously manifesting increased
solubility.25,26,34 In contrast to the sugar and amide termini of novobiocin, limited structure-
activity relationship studies have been conducted on the central coumarin core.32 Therefore,
structure-activity relationship studies for the coumarin core were pursued in an effort to
develop more potent inhibitors and to explore this region for improved inhibitory activity.
Construction of these novobiocin analogues were begun by replacing the central coumarin
core with naphthalene, quinolinone and quinoline surrogates, Such motifs are abundant in
natural products such as quinine, campothecin and cinchonidine, which manifest broad
biological activities including anticancer, antimycobacterial, antimicrobial, anticonvulsant,
anti-inflammatory and cardiovascular activities.35–41 The synthesis and structure-activity
relationships of naphthalene, quinolinone, and quinolone replacements of the novobiocin
coumarin core are presented in this article.
Results and Discussion
Design of New Novobiocin Analogues
Modifications to three regions of novobiocin were pursued to reveal structure-activity
relationships and to provide more efficacious compounds; 1) replacement of the central
coumarin core with various heterocycles were investigated, 2) modifications to the 2-
hydroxyl group of the corresponding 2-quinolinol tautomer ring system were prepared, and
3) modifications to the benzamide side chain were also pursued. Both, noviose (3) and the
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sugar surrogate N-methyl-4-piperidine, were chosen based upon prior studies with
novobiocin. Similarly, the side chain was replaced with an optimized prenylated or biaryl
side chain for further investigation of these new scaffolds. As shown in Figure 2, analogues
containing the prenylated benzamide side chain were assembled via three components; 1) a
central bicyclic aryl core (naphthalene or quinoline or quinolinone scaffold), 2) a prenylated
benzoic acid 4, and 3) noviose. The prenylated acid (4) could be coupled with the amino
group enlisting 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI) as the coupling
agent. Addition of noviose could then be achieved via the coupling of the
trichloroacetimidate of noviose carbonate with the phenol. The naphthalene core could be
prepared from commercially available 6-bromonaphthalen-2-ol (9) and both the quinolinone
or quinoline cores were envisioned for construction from commercially available 2-
methyl-3-nitrophenol (8).
Synthesis of the naphthalene-containing analogues commenced by introduction of a methyl
group at the 2-position of commercially available 6-bromonaphthalen-2-ol (9, Scheme 1) via
a three-step procedure. Reductive amination of 9 with formaldehyde and N,N-
dimethylamine followed by acylation of the phenol and subsequent reductive cleavage of
N,N-dimethylamine furnished 6-bromo-1-methylnaphthalen-2-ol (10), in quantitative
yield.42 The phenol was then protected as the methoxymethyl ether (MOM) to give
compound 11 (Scheme 1) for use in subsequent steps.
Construction of the quinolinone- and quinolone-containing analogues was accomplished via
methylation of 2-hydroxy-3-nitrophenol using potassium carbonate and methyl iodide,
followed by reduction of the nitro group to afford the corresponding aniline, 12 (Scheme 2).
Treatment of 12 with trans-cinnamoyl chloride gave amide 7, which underwent
intramolecular cyclization upon addition of aluminum chloride in chlorobenzene at 120 °C
to give 8-methylquinoline-2,7-diol (6) in high yield.43 It is noteworthy that purification was
not required until this point, as prior steps gave compounds in exceptional yields and purity.
To incorporate alkyl ethers at the 2-position, the 7-phenol was selectively protected as the
corresponding benzyl ether by the use of one equivalent of benzyl bromide and potassium
carbonate. Taking advantage of the dynamic equilibrium that exists between the quinolone
(6) and its quinolinol isomer, various hydrophobic groups were introduced at the 2-position.
Treatment of compound 13 with alkyl halides in the presence of potassium carbonate
afforded the corresponding alkyl ethers, 14–17, which were exposed to N-bromosuccinimide
to give the brominated compounds, 18–21, in excellent yields (Scheme 2). The brominated
compounds (11, 18–21) served as precursors for introduction of the amine and subsequent
attachment of the benzamide side chain.
For direct comparison, quinoline analogues were also pursued. Preparation of quinoline
precursors 23 and 24 began with quinolinol intermediate 13, which upon heating in the
presence of phosphorous oxychloride, and subsequent hydrogenation gave the quinoline
intermediate 5 as a yellow amorphous solid (Scheme 3).44 The phenolic moiety of 5 was
then protected as the tert-butyl-carbonate to provide steric hindrance and enable
regioselective bromination. In the event, bromination of 5 was achieved upon the addition of
bromine to a solution of 5 in carbon tetrachloride and pyridine.32 Subsequent addition of
methanolic HCl led to cleavage of the carbonate and formation of the corresponding phenol
22, which was then modified with methoxy methyl chloride or benzyl bromide to give
intermediates 23 and 24, respectively.
Introduction of the benzamide side chain was accomplished by utilization of the brominated
derivatives, 11, 18–21, 23, 24 which were transformed into the corresponding anilines, 25–
31, via two different conditions (Scheme 4).45, 46 Compounds 11, 18–21, 23, 24, were
heated in a sealed tube with copper nanoparticles, azidotrimethyl silane, and amino ethanol
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in a solution of dimethyl acetamide to give anilines 25–31.46 The protecting groups on
compounds 27–29 were exchanged from benzyl ethers to silyl ethers by hydrogenolysis on
palladium/carbon and subsequent O-silylation with tert-butyldimethylsilyl chloride
(TBSCl), which gave anilines 32–34. Anilines 25, 26, 31–34, were readily coupled with
benzoic acid 4 enlisting N-(3-(dimethylamino)propyl)-N′-ethylcarbodiimide hydrochloride
(EDCI) in a solution of pyridine and dichloromethane to give the corresponding amides, 35–
40.47 Deprotection of the benzyl or methoxy methyl or tert-butyldimethyl silyl groups of
35–40 was readily achieved with freshly prepared lithium di-tert-butyl biphenyl (LiDBB) in
THF, 4N HCl, or 1.0 M tetrabutylammonium fluoride, respectively. The free phenols of 41–
46 were provided without modification of the olefinic side chain (Scheme 4).48, 49
Upon construction of the phenols, the noviose appendage was attached via published
procedures.50 Phenols 41–46 were noviosylated with the trichloroacetimidate of noviose
carbonate, 47, in the presence of boron trifluoride etherate to provide the corresponding
carbonylated noviose products, which upon solvolysis with methanolic triethylamine
afforded 48–53 in good yields (Scheme 5).
Biological evaluation of prenylated benzamide side chain containing coumarin surrogates
Upon construction of analogues 48–53, evaluation of anti-proliferative activity against
SKBr3 (estrogen receptor negative, Her2 over-expressing breast cancer cells), MCF-7
(estrogen receptor positive breast cancer cells), LNCap (androgen-sensitive human prostate
adenocarcinoma), 253B J-V (human bladder cancer), and PC3mm2 (androgen receptor
insensitive prostate cancer) cell lines were investigated. Anti-proliferative activity of
noviose containing analogues is shown in Table 1. Analogues lacking the coumarin core
(49–50) manifested comparable activity to the corresponding coumarin-derived compounds,
which confirms the lactone is not required for Hsp90 inhibition. These analogues also
manifested comparable activities to DHN1 and DHN2 and manifested ~100-fold greater
inhibitory activity than the natural product, novobiocin.31 Quinoline analogue 50 was found
to be more efficacious (IC50 = 7.22 μ M against SKBr3 and IC50 = 0.26 μ M against PC3
cell lines) than the corresponding quinolinone (49) and naphthalene (48) analogues.
Introduction of steric bulk at the 2-position of the quinolinol (51–53) revealed the ethoxy
group (51) to be most active against both SKBr3 (IC50 = 1.94 μ M) and MCF7 (IC50 = 2.48
μM) cell lines. Given that analogue 51 (O-Et) manifested ~7-fold greater activity than
analogue 53 (O-CH2CH2Ph) suggests that sterics are moderately tolerated.
After evaluation of the analogues that contain the prenylated benzamide side chain, the
previously optimized biaryl acid, 55, was incorporated to further investigate the activity of
these scaffolds. Previous studies have shown that analogues possessing a biaryl benzamide
side chain manifest anti-proliferation activities comparable to analogues containing the
prenylated benzamide. As shown in Figure 3, the biaryl derivatives can be readily prepared
by a Suzuki coupling reaction between commercially available boronic acids and the
corresponding aryl iodide, followed by hydrolysis of the ester. Retrosynthesis of the biaryl
amide analogues follows a similar method as that used to prepare prenylated benzamide
derivatives. The biaryl amide analogues were assembled from three components, the central
core containing naphthalene, quinoline or quinolinone scaffold, the biaryl acid (55), and the
noviose sugar (3) or its surrogate 1-methylpiperidin-4-ol (54).
Synthesis of these biaryl analogues began with a N-(3-(dimethylamino)propyl)-N′-
ethylcarbodiimide (EDCI)-mediated coupling of aniline intermediates 26–31 with biaryl
acid 55 to give the corresponding amides, which upon cleavage of the benzyl or methoxy
methyl groups gave the free phenols, 62–68 (Scheme 6). The resulting phenols were coupled
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with the trichloroacetimidate of noviose carbonate (48) in the presence of boron trifluoride
etherate, followed by solvolysis of the cyclic carbonate to afford 69–74 (Scheme 7). 50
Evaluation of the anti-proliferative activities produced by analogues containing the biaryl
benzamide moiety (69–74) against multiple cancer cell lines supported the nitrogen atom to
be beneficial at the 1-position, as naphthalene analogues 69 and 70 were found to be 4- to 6-
fold less active than corresponding quinoline analogue, 74 (Table 2). Increased steric bulk at
the 2- position (71–73) was tolerated to some extent as both the ethyl and n-butyl ether
manifested potency comparable to the unsubstituted analogue 74, however, introduction of
bulkier groups (73) led to decreased potency.
Synthesis of noviose analogues containing alkyl or alkyl amine at the 2-position
Biological evaluation of quinoline containing analogues with the biaryl and prenylated side
chains suggested that the binding pocket at the 2-position could be further probed for
additional interactions, and perhaps greater inhibitory activity. Therefore, amines containing
a 2- or 3- carbon linker consistent with the 2-ethoxy group were chosen for investigation
(Figure 4). In addition, 2-bromoethoxy and the cyclohexyl ether of 2-phenol were prepared.
Analogues containing the alkyl side chains (a–h, Figure 4) at the 2-position were prepared
by coupling the noviosylated intermediate 75 with various alcohols using standard
Mitsunobu conditions followed by solvolysis of the carbonate to give coupled products, 76–
80 (Scheme 8). Hydrogenolysis of the benzyl group on 80 afforded the secondary-amino
analogue, 81. Treatment of 75 with dibromopropane in the presence of potassium carbonate,
followed by solvolysis of the cyclic carbonate gave intermediate 83, which upon subsequent
nucleophilic displacement with amines gave compounds 84 and 86, and subsequent
hydrogenolysis gave 85.
Biological evaluation of analogues containing aminoalkyl substitutions at the 2-position
revealed these substitutions to be beneficial as the majority of analogues manifested low
micromolar to nanomolar activities against multiple cancer cell lines (Table 2). Their
efficacy was greater than compounds containing the alkyl substituents (71–73 & 79). The
two most potent analogues from this series were 77 (IC50 = 0.21±0.04 μM against MCF-7
cell line) and 85 (IC50 = 0.12±0.04 μM against MCF-7 cell line), which contain a 3-carbon
linker between the quinolinol oxygen and the basic amine. Increased steric bulk as found in
86 resulted in decreased activity. Direct comparison of the 4-piperidine containing analogue,
78, with that containing a cyclohexane ring (79) suggests that the presence of charged group
can provide improved activity. Overall, these results indicate that an amine attached to a 3-
carbon linker is optimal at the 2-postion. Replacement of terminal primary-amine (76) with
a tertiary-amine (77) resulted in increased efficacy against multiple cell lines. In summary,
presence of hydrophilic amino group in the binding pocked enhances potency to a greater
extant than increased lipophilicity.
Design and Synthesis of mono- and diamino substituted coumarin surrogate analogues
Encouraged by the efficacy manifested by noviose containing biaryl analogues that also
contain an aminoalkyl substituent at the 2-position (76–78, 81, 83, 85, 86), compounds
containing the noviose surrogate, N-methylpiperidine, were pursued (Scheme 9). N-
Methylpiperidine is a readily available surrogate for the synthetically complex noviose
sugar. 24, 32 Coupling of phenols 62, 63, 65–68 with 1-methylpiperidin-4-ol was achieved
under Mitsunobu conditions employing diisopropyl azodicarboxylate (DIAD) and
triphenylphosphine to give 87–92.26 Analogues containing aminoalkyl ethers at the 2-
position were synthesized from diphenol 63, which upon treatment with five equivalents of
piperidin-4-ol or 3-(dimethylamino)propan-1-ol gave analogues 93–94. Construction of 96
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and 98 was accomplished from the phenol 64, which was obtained during partial
hydrogenolysis of dibenzylated compound, 57. Treatment of 64 with dibromopropane in the
presence of potassium carbonate, followed by coupling with 1-methylpiperazine gave 95.
Subsequent hydrogenolysis of 95, followed by coupling of the corresponding phenol with 4
gave 96. Analogue 98 was synthesized from phenol 64 in a similar manner enlisting 3-
(dimethylamino)propan-1-ol.
Results from the biological investigation of diamino analogues (87–94, 96 & 98) are shown
in Table 3. These results confirm that the synthetically challenging noviose moiety can be
replaced with commercially available amines without lowering potency as analogues 87–92
manifested IC50 values similar to compounds utilizing noviose (69–74). Biological
evaluation of analogues containing alkyl amine substituents at the 2-position (93, 94, 96, 98)
confirmed that N, N-dimethylpropylamine is an optimal substituent at the 2-position as
analogue 108 manifested good potency against breast cancer (SKBr3; IC50 = 0.59±0.05
μM), prostate cancer (PC3MM2; IC50 = 0.409 μM) and, lung cancer (LNCaP; IC50 = 0.253
μM) cell lines. In contrast to noviose containing analogue 78, the corresponding N-
methylpiperidine containing analogue 94 manifested better efficacy against the PC3MM2
and LNCaP cell lines. Replacement of N-methylpiperidine at the 7-position with acyclic N,
N-dimethylpropylamine resulted in less activity.
To confirm these analogues manifest inhibitory anti-proliferative activity through Hsp90
inhibition, western blot analyses of cell lysates resulting from the incubation of cells treated
with the three most potent compounds 77, 85, and 94 for twenty four hours were performed.
As shown in Figure 4, compound 77, 85 and, 94 induced degradation of Hsp90-dependent
client proteins p-Akt and Her2. Whereas, actin levels remained unchanged. Actin is not an
Hsp90-dependent substrate and used as a control. Absence of induction of heat shock
response as indicated by constant levels of Hsp90 indicates that these compounds exhibit
Hsp90 inhibitory activity through C-terminal inhibition.
In summary, the coumarin core of novobiocin has been replaced with a quinolinone,
naphthalene, or quinolone ring system. These replacements resulted in the efficacious
quinoline class of Hsp90 inhibitors that allowed probing at the 2-position to gain additional
interactions with Hsp90. Addition of alkylamino substituents at the 2-position led to new
analogues that exhibit increased activity against various cancer cell lines and analogue 87
was found to be the most potent, which manifested ~200 nm activity against the SKBr3 cell
line. These results suggest that binding pocket surrounding the 2-phenolic position may be
important for the development of more efficacious compounds.
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Retrosynthetic analysis of novobiocin analogues
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Retrosynthetic analysis of biaryl amide-containing analogues
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Selected alkyl amines and alkyl groups for probing the 2-position.
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Western blot analyses of Hsp90 client protein degradation in MCF-7 breast cancer cell line.
L represents a concentration ½ × IC50 value while H represents a concentration of 5 × IC50
value. GDA (500 nM) represents a positive control, while DMSO, vehicle, serves as the
negative control.
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